How Does Nesiritide Work? Mechanism of Action, Per the Research

This page summarises how the published pharmacology literature describes the mechanism of nesiritide. It separates receptor-level actions that are well characterised from downstream effects inferred largely from preclinical models. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medical condition or treatment. No dosing, administration or protocol information is provided here.

What Nesiritide Is, in Pharmacological Terms

Nesiritide is a recombinant form of human B-type natriuretic peptide (BNP), the cardiac hormone whose structure, receptor families and physiological functions were catalogued in a 2009 pharmacology review of the natriuretic peptide system (PMID 19089336). A 2008 review of the molecular and physiological effects of nesiritide described it as an exogenous replica of endogenous BNP, acting through the same receptor system rather than through a novel target (PMID 18629383). A 2023 scientific statement from the Heart Failure Association of the ESC, the Heart Failure Society of America and the Japanese Heart Failure Society described BNP as a peptide released by cardiomyocytes in response to wall stress, which is why circulating natriuretic peptides are used as markers of cardiac loading (PMID 37098791). A 2018 review of newer hormonal pharmacotherapies for heart failure placed nesiritide within the broader class of hormone-based agents developed for the syndrome (PMID 30063443).

The Established Receptor Target: NPR-A and cGMP

The 2009 pharmacology review reported that BNP binds natriuretic peptide receptor A (NPR-A, also called guanylyl cyclase A), a single-transmembrane receptor whose intracellular domain is itself a guanylyl cyclase (PMID 19089336). That same review described ligand binding as activating the cyclase domain, converting GTP to cyclic GMP and raising intracellular cGMP concentrations in vascular smooth muscle, endothelium and renal tissue (PMID 19089336). The 2008 nesiritide review reported that the rise in cGMP is the proximal signal underlying the agent's measured physiological effects, with cGMP-dependent protein kinase (protein kinase G) acting as the principal downstream effector (PMID 18629383).

From cGMP to Smooth Muscle Relaxation

Researchers describing the natriuretic peptide system reported that protein kinase G activation lowers intracellular calcium availability in vascular smooth muscle, producing relaxation of both capacitance and resistance vessels (PMID 19089336). A 2025 scientific statement of the Heart Failure Association of the ESC on agents with vasodilator properties in acute heart failure grouped natriuretic peptide-based agents with other vasodilators that act by reducing ventricular loading conditions (PMID 40320261). In an intensivist-oriented 2019 review of cardiogenic pulmonary oedema, vasodilator mechanisms were described in terms of reduced venous return and reduced afterload, which together lower filling pressures (PMID 31116110).

Clearance Pathways That Shape the Signal

The 2009 review reported that the natriuretic peptide system includes a third receptor, NPR-C, which lacks a guanylyl cyclase domain and functions mainly in ligand internalisation and clearance (PMID 19089336). That review also described enzymatic degradation by neprilysin (neutral endopeptidase) as a second route of elimination for natriuretic peptides, a pathway that later became a drug target in its own right (PMID 19089336). The 2018 hormonal pharmacotherapy review discussed how strategies to augment natriuretic peptide signalling have included both exogenous peptide administration and inhibition of peptide breakdown (PMID 30063443). The 2015 translational review of BNP preclinical and clinical trial data noted that the balance between receptor-mediated signalling and clearance helps explain why circulating peptide concentrations and biological effect are not always proportional (PMID 25771949).

Downstream Physiology Described in the Literature

Haemodynamic Effects

The 2008 review of nesiritide's molecular and physiological effects reported venous and arterial dilation as the dominant haemodynamic consequence of NPR-A activation, lowering preload and afterload (PMID 18629383). The 2025 HFA statement on vasodilator-acting agents in acute heart failure described this class of effects as a reduction in congestion-related loading rather than a direct inotropic action (PMID 40320261). A 2019 review of shock classification and the pathophysiological principles of therapeutics discussed vasodilatory and vasoactive agents in terms of their effects on preload, afterload and tissue perfusion, framing the physiological trade-offs involved (PMID 30543176).

Renal and Natriuretic Effects

The 2009 pharmacology review reported that natriuretic peptide receptor activation in the kidney promotes sodium excretion and diuresis, effects for which the peptide family is named (PMID 19089336). The 2008 nesiritide review described natriuretic and diuretic responses as part of the integrated physiological profile attributed to the agent (PMID 18629383). A 2016 review of therapeutic strategies for haemodynamic cardiorenal syndrome discussed natriuretic peptide-based approaches among interventions examined where cardiac and renal dysfunction interact (PMID 26989394). A 2014 review of cardiac surgery-associated acute kidney injury included natriuretic peptides among the pharmacological strategies that have been investigated for renal protection in that setting (PMID 25196567).

Neurohormonal Interactions

The 2008 review reported that natriuretic peptide signalling opposes the renin-angiotensin-aldosterone axis, including suppression of aldosterone release (PMID 18629383). The 2009 pharmacology review described the natriuretic peptide system as a physiological counter-regulatory arm to sodium-retaining and vasoconstrictor hormones (PMID 19089336). The 2018 hormonal pharmacotherapy review framed heart failure therapeutics partly as attempts to shift the balance between these opposing hormonal systems (PMID 30063443).

Established Mechanism Versus Proposed Mechanism

The table below separates receptor-level and physiological actions that are consistently described in pharmacology reviews from actions that the literature characterises largely on the basis of preclinical or mechanistic work.

The 2015 review of BNP preclinical and clinical trial data reported that antifibrotic and antiremodelling properties of BNP were demonstrated mainly in preclinical models, and that translating those findings into clinical endpoints proved more complicated (PMID 25771949). A 2019 review of peptides as epigenetic modulators described how peptides more generally have been proposed to influence gene-regulatory processes, a line of enquiry separate from the receptor pharmacology of nesiritide and not a demonstrated mechanism for it (PMID 31300053).

Why Mechanism and Clinical Result Can Diverge

The 2015 translational review reported that despite a coherent receptor-level rationale, the clinical trial record for BNP-based therapy in heart failure was debated, and researchers continued to analyse why mechanistic promise did not map neatly onto clinical endpoints (PMID 25771949). The 2016 cardiorenal review described the difficulty of predicting renal response in patients whose cardiac and renal physiology are simultaneously deranged (PMID 26989394). The 2025 HFA statement emphasised that vasodilator pharmacology in acute heart failure has to be understood against variable loading conditions, perfusion pressure and comorbidity rather than as a fixed effect (PMID 40320261). A 2001 endocrinology survey noted the emergence of natriuretic peptide-based therapeutics during that period, illustrating how long this mechanism has been under study (PMID 11284421).

Mechanism-Linked Adverse Effects: What Studies Report

Because the proximal mechanism is vasodilation, the most frequently discussed adverse effect is the mechanistic extension of that action. The 2025 HFA scientific statement on vasodilator-acting agents reported hypotension as the principal limiting effect associated with vasodilator therapy in acute heart failure, and discussed blood-pressure monitoring as integral to the use of this class (PMID 40320261). The 2015 review of BNP preclinical and clinical trial data reported that blood pressure reduction and uncertainty over renal effects were central to debate about BNP-based therapy (PMID 25771949). The 2016 cardiorenal review discussed how changes in perfusion pressure can influence renal function in patients with combined cardiac and renal disease (PMID 26989394). The 2019 shock review similarly framed the hazards of lowering vascular tone in states where perfusion pressure is already marginal (PMID 30543176).

What the Mechanism Literature Does Not Establish

• Receptor-level findings describe signalling, not clinical benefit; the 2015 review reported that preclinical signals and clinical trial results diverged for BNP-based therapy (PMID 25771949).
• Natriuretic peptide measurement in patients reflects cardiac wall stress and is used diagnostically, which is a separate question from exogenous peptide administration (PMID 37098791).
• Renal protection in specific surgical settings has been investigated rather than settled, according to a review of cardiac surgery-associated acute kidney injury (PMID 25196567).
• Antifibrotic and antiproliferative effects remain proposed mechanisms derived predominantly from preclinical work (PMID 25771949).

Related Reading

For a broader overview of the compound, including its research context and the literature base, see the nesiritide overview on PeptideU. Nesiritide is a prescription agent in the jurisdictions where it has been marketed; nothing on this page describes administration, and nothing here is a recommendation.

References

• Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications (Handbook of Experimental Pharmacology, 2009)
• Molecular and physiological effects of nesiritide (The Canadian Journal of Cardiology, 2008)
• BNP and Heart Failure: Preclinical and Clinical Trial Data (Journal of Cardiovascular Translational Research, 2015)
• Pathophysiology and clinical use of agents with vasodilator properties in acute heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC (European Journal of Heart Failure, 2025)
• Natriuretic peptides: role in the diagnosis and management of heart failure (European Journal of Heart Failure, 2023)
• Newer hormonal pharmacotherapies for heart failure (Expert Review of Endocrinology & Metabolism, 2018)
• Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome (Cardiorenal Medicine, 2016)
• Cardiac surgery-associated acute kidney injury (Blood Purification, 2014)
• Cardiogenic pulmonary edema: mechanisms and treatment - an intensivist's view (Current Opinion in Critical Care, 2019)
• Shock - Classification and Pathophysiological Principles of Therapeutics (Current Cardiology Reviews, 2019)
• Peptides as epigenetic modulators: therapeutic implications (Clinical Epigenetics, 2019)
• [Endocrinology 1999-2000] (Casopis Lekaru Ceskych, 2001)